CONTROLLING ACCESS TO USER INTERFACES

1 . A method of controlling access to user interfaces, comprising:

identifying, by one or more processors, a plurality of user interfaces to present digital therapeutic content to a user to address a condition using one or more of the plurality of user interfaces;

providing, by the one or more processors, to a user device associated with the user over a time window, access to a subset of the plurality of user interfaces to present a corresponding portion of the digital therapeutic content to the user;

receiving, by the one or more processors, data from the user device, the data identifying interactions by the user with one or more of the subset of the plurality of user interfaces;

determining, by the one or more processors, that the interactions by the user satisfy a criterion with the corresponding portion of the digital therapeutic content within the time window, based on the data from the user device; and

providing, by the one or more processors, to the user device, access to the plurality of user interfaces to present an entirety of the digital therapeutic content to the user, responsive to determining that the interactions satisfy the criterion.

2 . The method of claim 1 , wherein determining that the user satisfy the criterion further comprises determining that the corresponding portion of the digital therapeutic content is effective at addressing the condition associated with the user within the time period, based on the data.

3 . The method of claim 1 , further comprising:

determining, by the one or more processors, that second interactions by the user do not satisfy the criterion with the corresponding portion of the digital therapeutic content within the time window, based on second data from the user device; and

refraining, by the one or more processors, from providing the user device access to the plurality of user interfaces to present the entirety of the digital therapeutic content, responsive to determining that the second interactions do not satisfy the criterion.

4 . The method of claim 1 , further comprising generating, by the one or more processors, an access code to provide the user device access to the plurality of user interfaces for the entirety of the digital therapeutic content, responsive to determining that the interactions satisfy the criterion, and

wherein providing the user device access to the plurality of user interfaces further comprises providing the user device access to the plurality of user interfaces, responsive to entry of the access code via the user device.

5 . The method of claim 1 , wherein providing the user device access to the subset of the plurality of user interfaces further comprises providing the user device access to a second user interface different from any of the plurality of user interfaces.

6 . The method of claim 1 , wherein the user is on a medication to address the condition, in at least partial concurrence with at least one of (i) provision of the subset of the plurality of user interfaces for the portion of the digital therapeutic content or (ii) provision of the plurality of user interfaces for the entirety of the digital therapeutic content.

7 . The method of claim 1 , wherein the condition comprises at least one of: substance use disorder, opioid use disorder, chronic insomnia, alcohol use disorder, schizophrenia, generalized anxiety disorder, major depressive disorder, bipolar, posttraumatic stress disorder, acute and chronic pain, migraine, multiple sclerosis, epilepsy, irritable bowel syndrome, specialty gastroenterology, cancer, or cardiovascular disease.

8 . A method of controlling access to user interfaces, comprising:

identifying, by one or more processors, a plurality of user interfaces to present digital therapeutic content to a user to address a condition using one or more of the plurality of user interfaces;

providing, by the one or more processors, to a user device associated with the user, access to a subset of the plurality of user interfaces to present a corresponding portion of the digital therapeutic content to the user;

receiving, by the one or more processors, an indication to provide access to the entirety of the digital therapeutic content to the user; and

providing, by the one or more processors, to the user device, access to the plurality of user interfaces to present an entirety of the digital therapeutic content to the user, responsive to receiving the indication to approve access.

9 . The method of claim 8 , further comprising:

determining, by the one or more processors, that a time window for providing the user device access to the subset of the plurality of user interfaces has expired; and

restricting, by the one or more processors, the user device from accessing the subset of the plurality of user interfaces, responsive to determining that the time window has expired.

10 . The method of claim 8 , further comprising generating, by the one or more processors, an access code to provide the user device access to the subset of the plurality of user interfaces, responsive to the indication to provide the digital therapeutic content to the user, and

wherein providing the user device access to the subset of the plurality of user interfaces further comprises providing the user device access to the subset of the plurality of user interfaces, responsive to entry of the access code via the user device.

11 . The method of claim 8 , further comprising:

selecting, by the one or more processors, from a second plurality of user interfaces, a second user interface to add to the subset of the plurality of user interfaces based on data from the user device, the data identifying interactions by the user with one or more of the subset of the plurality of user interfaces; and

providing, by the one or more processors, to the user device, access to the second user interface in addition to the subset of the plurality of user interfaces.

12 . The method of claim 8 , further comprising generating, by the one or more processors, an access code to provide the user device access to the plurality of user interfaces for the entirety of the digital therapeutic content, and

wherein providing the user device access to the plurality of user interfaces further comprises providing the user device access to the plurality of user interfaces, responsive to entry of the access code via the user device.

13 . The method of claim 8 , wherein receiving the indication further comprises receiving the indication responsive to an approval by a remote service of the provision of the entirety of the digital therapeutic content to the user.

14 . The method of claim 8 , wherein the user is on a medication to address the condition, in at least partial concurrence with at least one of (i) provision of the subset of the plurality of user interfaces for the portion of the digital therapeutic content or (ii) provision of the plurality of user interfaces for the entirety of the digital therapeutic content.

15 . The method of claim 8 , wherein the condition comprises at least one of: substance use disorder, opioid use disorder, chronic insomnia, alcohol use disorder, schizophrenia, generalized anxiety disorder, major depressive disorder, bipolar, posttraumatic stress disorder, acute and chronic pain, migraine, multiple sclerosis, epilepsy, irritable bowel syndrome, specialty gastroenterology, cancer, or cardiovascular disease.

16 . A system for controlling access to user interfaces, comprising:

one or more processors coupled with memory, configured to:

identify a plurality of user interfaces to present digital therapeutic content to a user to address a condition using one or more of the plurality of user interfaces;

provide, to a user device associated with the user over a time window, access to a subset of the plurality of user interfaces to present a corresponding portion of the digital therapeutic content to the user;

receive data from the user device, the data identifying interactions by the user with one or more of the subset of the plurality of user interfaces;

determine that the interactions by the user satisfy a criterion with the corresponding portion of the digital therapeutic content within the time window, based on the data from the user device; and

provide, to the user device, access to the plurality of user interfaces to present an entirety of the digital therapeutic content to the user, responsive to determining that the interactions satisfy the criterion.

17 . The system of claim 16 , wherein the one or more processors are further configured to determine that the corresponding portion of the digital therapeutic content is effective at addressing the condition associated with the user within the time period, based on the data.

18 . The system of claim 16 , wherein the one or more processors are further configured to:

determine that second interactions by the user do not satisfy the criterion with the corresponding portion of the digital therapeutic content within the time window, based on second data from the user device; and

refrain from providing the user device access to the plurality of user interfaces to present the entirety of the digital therapeutic content, responsive to determining that the second interactions do not satisfy the criterion.

19 . The system of claim 16 , wherein the one or more processors are further configured to:

generate an access code to provide the user device access to the plurality of user interfaces for the entirety of the digital therapeutic content, responsive to determining that the interactions satisfy the criterion, and

provide the user device access to the plurality of user interfaces, responsive to entry of the access code via the user device.

20 . The system of claim 16 , wherein the one or more processors are further configured to provide the user device access to a second user interface different from any of the plurality of user interfaces.

21 . The system of claim 16 , wherein the user is on a medication to address the condition, in at least partial concurrence with at least one of (i) provision of the subset of the plurality of user interfaces for the portion of the digital therapeutic content or (ii) provision of the plurality of user interfaces for the entirety of the digital therapeutic content.

22 . The system of claim 16 , wherein the condition comprises at least one of: substance use disorder, opioid use disorder, chronic insomnia, alcohol use disorder, schizophrenia, generalized anxiety disorder, major depressive disorder, bipolar, posttraumatic stress disorder, acute and chronic pain, migraine, multiple sclerosis, epilepsy, irritable bowel syndrome, specialty gastroenterology, cancer, or cardiovascular disease.

23 . A system for controlling access to user interfaces, comprising:

one or more processors coupled with memory, configured to:

identify a plurality of user interfaces to present digital therapeutic content to a user to address a condition using one or more of the plurality of user interfaces;

provide, to a user device associated with the user over a time window, access to a subset of the plurality of user interfaces to present a corresponding portion of the digital therapeutic content to the user;

receive an indication to provide access to the entirety of the digital therapeutic content to the user; and

provide, to the user device, access to the plurality of user interfaces to present an entirety of the digital therapeutic content to the user, responsive to receiving the indication to approve access.

24 . The system of claim 23 , wherein the one or more processors are configured to

determine that the time window for providing the user device access to the subset of the plurality of user interfaces has expired; and

restrict the user device from accessing the subset of the plurality of user interfaces, responsive to determining that the time window has expired.

25 . The system of claim 23 , wherein the one or more processors are configured to:

generate an access code to provide the user device access to the subset of the plurality of user interfaces, responsive to the indication to provide the digital therapeutic content to the user, and

provide the user device access to the subset of the plurality of user interfaces, responsive to entry of the access code via the user device.

26 . The system of claim 23 , wherein the one or more processors are configured to:

select, from a second plurality of user interfaces, a second user interface to add to the subset of the plurality of user interfaces, in response to the indication, based on data from the user device, the data identifying interactions by the user with one or more of the subset of the plurality of user interfaces; and

provide, to the user device, access to the second user interface in addition to the subset of the plurality of user interfaces.

27 . The system of claim 23 , wherein the one or more processors are configured to:

generate an access code to provide the user device access to the plurality of user interfaces for the entirety of the digital therapeutic content, and

provide the user device access to the plurality of user interfaces, responsive to entry of the access code via the user device.

28 . The system of claim 23 , wherein the one or more processors are configured to receive the indication responsive to an approval by a remote service of the provision of the entirety of the digital therapeutic content to the user.

29 . The system of claim 23 , wherein the user is on a medication to address the condition, in at least partial concurrence with at least one of (i) provision of the subset of the plurality of user interfaces for the portion of the digital therapeutic content or (ii) provision of the plurality of user interfaces for the entirety of the digital therapeutic content.

30 . The system of claim 23 , wherein the condition comprises at least one of: substance use disorder, opioid use disorder, chronic insomnia, alcohol use disorder, schizophrenia, generalized anxiety disorder, major depressive disorder, bipolar, posttraumatic stress disorder, acute and chronic pain, migraine, multiple sclerosis, epilepsy, irritable bowel syndrome, specialty gastroenterology, cancer, or cardiovascular disease.